21 research outputs found
Venous thromboembolism risk score during hospitalization in pregnancy: results of 10694 prospective evaluations in a clinical trial
Objectives: Hospitalization during pregnancy and childbirth increases the risk of Venous Thromboembolism Risk (VTE). This study applied a VTE risk score to all hospitalized pregnant women to ascertain its effectiveness in preventing maternal death from VTE until 3 months after discharge.
Methods: In this interventional study, patients were classified as low- or high-risk according to the VTE risk score (Clinics Hospital risk score). High-risk patients (score ≥ 3) were scheduled for pharmacological Thromboprophylaxis (TPX). Interaction analysis of the main risk factors was performed using Odds Ratio (OR) and Poisson regression with robust variance.
Results: The data of 10694 cases (7212 patients) were analyzed; 1626 (15.2%, 1000 patients) and 9068 (84.8%, 6212 patients) cases were classified as high-risk (score ≥ 3) and low-risk (score < 3), respectively. The main risk factors (Odds Ratio, 95% Confidence Interval) for VTE were age ≥ 35 and < 40 years (1.6, 1.4–1.8), parity ≥ 3 (3.5, 3.0–4.0), age ≥ 40 years (4.8, 4.1–5.6), multiple pregnancies (2.1, 1.7–2.5), BMI ≥ 40 kg/m2 (5.1, 4.3–6.0), severe infection (4.1, 3.3–5.1), and cancer (12.3, 8.8–17.2). There were 10 cases of VTE: 7/1636 (0.4%) and 3/9068 (0.03%) in the high- and low-risk groups, respectively. No patient died of VTE. The intervention reduced the VTE risk by 87%; the number needed to treat was 3.
Conclusions: This VTE risk score was effective in preventing maternal deaths from VTE, with a low indication for TPX. Maternal age, multiparity, obesity, severe infections, multiple pregnancies, and cancer were the main risk factors for VTE
Resultados gestacionais e trombofilias em mulheres com história de óbito fetal de repetição
Delivery complications and perinatal results in pregnant women with von Willebrand disease
OBJETIVO: Analisar as complicações maternas associadas ao parto e puerpério, bem como os resultados perinatais, em gestantes portadoras da doença de von Willebrand. MÉTODOS: Foram analisados os prontuários de todas as gestantes com diagnóstico de doença de von Willebrand, cujo parto foi realizado nesta instituição no perÃodo compreendido entre março de 2001 e agosto de 2007. Foram investigadas caracterÃsticas relativas à via de parto, incidência de complicações hemorrágicas no parto e no puerpério imediato, perfil dos exames laboratoriais maternos e resultados perinatais. As variáveis foram estudadas descritivamente, calculando-se freqüências absolutas e relativas, médias, medianas e desvios padrão. RESULTADOS: Foram revisadas 13 gestações em oito pacientes portadoras da doença. No perÃodo ocorreram 13.037 partos na instituição, perfazendo incidência de 0,1%. Seis pacientes (75%) apresentavam o tipo 1 da doença, e duas (25%) o tipo 2. No terceiro trimestre, a média da atividade do fator VIIIc foi de 98,5%. A cesárea foi realizada em nove casos (69%), cuja anestesia foi do tipo raquidiana em sete casos. Como complicação do parto, um caso evoluiu com descolamento prematuro da placenta e foi realizada a cesárea. Um caso apresentou sangramento no primeiro pós-parto, necessitando reposição do fator VIII. Em dois casos foi realizada a reposição profilática do fator VIII antes da cesárea. A restrição do crescimento fetal ocorreu em cinco casos (38,5%). O peso dos RNs apresentou média de 2676 gramas e um caso (7,8%) apresentou Apgar de 1º minuto inferior a sete. CONCLUSÃO: O parto em gestantes com diagnóstico de doença de von Willebrand tem evolução favorável quando cuidados são tomados procurando oferecer assistência especÃfica. O crescimento fetal deve ser monitorizado nessas gestantes.OBJECTIVE: To study maternal complication associated to delivery and the puerperium period in pregnancies affected by von Willebrand's disease. METHODS: Chart data of all the pregnant women with diagnosis of von Willebrand disease were retrospectively reviewed. All cases with von Willebrand's disease that had given birth at this institution, between March 2001 and August 2007, were analyzed. The following variables were investigated: mode of delivery, hemorrhage complications during delivery and postpartum, maternal blood exams and perinatal results. Variables were studied descriptively, using absolute and relative frequencies, means, medians and standard deviations. RESULTS: 13 pregnancies of eight women with the disease were reviewed. During this sane period, there were 13,037 deliveries in the institution, resulting in an incidence of 0.1%. Six women (75%) were type 1 disease and, two (25%) were type 2. The last Factor VIIIc activity presented a mean value of 98.5%. A Cesarean section was performed in nine pregnancies, with epidural anesthesia in seven. Delivery complication occurred in two cases: one presented placental abruption and a Cesarean was performed. The other, presented postpartum hemorrhage in the first day and required reposition with factor VIII. Two cases received factor VIII before Cesarean section. Fetal growth restriction was detected in five pregnancies (38.5%). Mean birth weight was of 2676 grams and one case presented 1st minute Apgar score below seven. CONCLUSION: Delivery in patients with von Willebrand disease has a favorable evolution when specific assistance is provided. In these pregnancies,fetal growth should be monitored
Complicações do parto e resultados perinatais em gestantes portadoras da doença de von Willebrand
Anemia During Pregnancy after Silastic Ring Roux-en-Y Gastric Bypass: Influence of Time to Conception
Bariatric surgery before pregnancy may help prevent obesity-related gestational complications. However, maternal malnutrition is not without potential risks during pregnancy. The objective was to evaluate the influence of time to conception after silastic ring Roux-en-Y gastric bypass (SRYGB) on maternal anemia. Patients who underwent SRYGB for morbid obesity and who subsequently became pregnant were followed up at the prenatal. Thirty pregnancies occurred between July 2001 and September 2009. The patients were analyzed according to time to conception after bariatric surgery: 17 patients with time to conception < 4 years (48 months) and 13 patients with a parts per thousand yen4 years. First trimester hemoglobin levels were significantly lower in patients with time to conception a parts per thousand yen4 years (48 months) (median 9.6 g/dL, range 5.8-13.2 g/dL) than in patients with time to conception < 4 years (median 11.1 g/dL, range 9.8-13.6 g/dL; p = 0.047). The need for intravenous iron therapy or packed red cell transfusion was significantly more frequent among women who became pregnant a parts per thousand yen4 years after SRYGB compared to < 4 years (30.8% vs. 0%, p = 0.026). Pregnancy after 4 years of SRYGB is associated with maternal anemia and the need for more strict iron supplementation
Effects of maternal anemia on computerized cardiotocography and fetal biophysical profile
OBJETIVOS: avaliar a influência dos nÃveis de hemoglobina (Hb) materna nos padrões da frequência cardÃaca fetal (FCF) e no perfil biofÃsico fetal (PBF) em gestações a termo. MÉTODOS: gestantes portadoras de anemia (Hb<11,0 g/dL) foram avaliadas prospectivamente, entre a 36ª e a 40ª semana de gestação, no perÃodo compreendido entre janeiro de 2008 e março de 2009. O Grupo Controle foi constituÃdo por gestantes de termo, saudáveis, com valores normais de hemoglobina (Hb>11,0 g/dL). Foram excluÃdos casos com anomalias ou restrição do crescimento fetal. A avaliação da FCF foi realizada pela cardiotocografia computadorizada (Sistema8002-Sonicaid) e análise do traçado com 30 minutos de exame. O PBF foi realizado em todas as pacientes. Foram utilizados os testes t de Student, teste do χ2 e teste exato de Fisher. O nÃvel de significância utilizado foi de 0,05. RESULTADOS: A média da Hb materna no grupo com anemia (n=18) foi de 9,4 g/dL (DP=1,4 g/dL) e no Grupo Controle 12,4 g/dL (DP=1,3 g/dL). Quanto aos parâmetros da cardiotocografia, não foi constatada diferença significativa nas médias entre os grupos com anemia e controle, respectivamente: FCF basal (131,3 bpm versus 133,7 bpm, p=0,5), acelerações da FCF > 10 bpm (7,9 versus. 8,2, p=0,866), acelerações da FCF > 15 bpm (5,2 versus 5,4, p=0,9), episódios de alta variação da FCF (17,1 versus 15,5 min, p=0,5), episódios de baixa variação da FCF (4,4 versus 3,6 min, p=0,6), e variação de curto prazo (10,5 versus 10,9 ms, p=0,5). Em ambos os grupos, todas as pacientes apresentaram PBF normal. CONCLUSÕES: este estudo sugere que a anemia materna leve ou moderada, sem outras comorbidades maternas ou fetais, não se associa a anormalidades nos parâmetros do perfil biofÃsico fetal e da FCF analisada pela cardiotocografia computadorizada.PURPOSES: to evaluate the influence of maternal hemoglobin (Hb) levels in the patterns of fetal heart rate (FHR) and in the fetal biophysical profile (FBP) in term gestations. METHODS: pregnant women with anemia (Hb<11.0 g/dL) were prospectively evaluated between the 36th and the 40th week of gestation, from January 2008 to March 2009. The Control Group was composed of term and healthy pregnant women, with normal values of hemoglobin (Hb>11,0 g/dL). Cases of anomalies or fetal growing restrictions were excluded. The FHR evaluation was performed by computerized cardiotocography (8002 System-Sonicaid), and by record analysis during 30 minutes of exam. The FBP was done in all the patients. Student's, χ2 and Fisher's exact tests were used, with 0.05 significance level. RESULTS: The average of maternal Hb in the group with anemia (n=18) was 9.4 g/dL (DP=1.4 g/dL), and in the control group, 12.4g/dL (DP=1.3 g/dL). There has been no significant mean differences between groups concerning the cardiotocography parameters, respectively: basal FHR(131.3 versus 133.7 bpm, p=0.5), FHR accelerations > 10b pm (7.9 versus 8.2, p=0.866), FHR accelerations > 15 bpm (5.2 versus. 5.4, p=0.9), episodes of high variation of the FHR (17.1 versus 15.5 min, p=0,5), episodes of variation of the FHR (4.4 versus 3.6 min, p=06), and short term variation (10.5 versus 10.9 ms, p=0.5). In both groups, all patients presented normal FBP. CONCLUSIONS: this study suggests that light or moderate maternal anemia, without other maternal or fetal comorbidity, is not associated with abnormalities in the parameters of fetal biophysical profile and of the FHR analyzed by computerized cardiotocography
Avaliação da vitalidade fetal em gestações complicadas pela plaquetopenia materna moderada ou grave Assessment of fetal well-being in pregnancies complicated by maternal moderate to severe thrombocytopenia
OBJETIVO: Analisar os resultados da avaliação da vitalidade fetal em gestações complicadas por plaquetopenia materna moderada ou grave. MÉTODOS: No perÃodo de abril de 2001 a julho de 2011, foram analisados, retrospectivamente, os dados de prontuários de 96 gestantes com diagnóstico de plaquetopenia na gestação. Foram analisados os seguintes exames de avaliação da vitalidade fetal realizados no perÃodo anteparto: cardiotocografia, perfil biofÃsico fetal, Ãndice de lÃquido amniótico e doplervelocimetria das artérias umbilicais. RESULTADOS: Foram analisadas 96 gestações com os seguintes diagnósticos: plaquetopenia gestacional (n=37, 38,5%), hiperesplenismo (n=32, 33,3%), púrpura trombocitopenica imune (PTI, n=14, 14,6%), plaquetopenia imune secundária (n=6, 6,3%), aplasia medular (n=3, 3,1%) e outros (n=4, 4,1%). A cardiotocografia apresentou resultado normal em 94% dos casos, o perfil biofÃsico fetal com Ãndice 8 ou 10 em 96,9% e o Ãndice de lÃquido amniótico >5,0 cm em 89,6%. A doplervelocimetria da artéria umbilical apresentou resultado normal em 96,9%. Na análise dos principais grupos de plaquetopenia, constatou-se que o diagnóstico de oligohidrâmnio foi significativamente mais frequente no grupo com PTI (28,6%) quando comparado aos demais (gestacional: 5,4% e hiperesplenismo: 9,4%, p=0,04). CONCLUSÕES: O presente estudo permitiu concluir que, nas gestações complicadas pela plaquetopenia materna moderada ou grave, apesar do bem-estar fetal manter-se preservado na grande maioria dos casos, em gestantes com PTI é importante o seguimento da vitalidade fetal com ênfase na avaliação do volume de lÃquido amniótico, devido à sua associação com a oligohidramnia.<br>PURPOSE: To analyze the results of assessment of fetal well-being in pregnancies complicated by moderate or severe maternal thrombocytopenia. METHODS: Data from April 2001 to July 2011 of 96 women with a diagnosis of thrombocytopenia in pregnancy were retrospectively analyzed. We analyzed the following tests performed during the antepartum period for fetal assessment: cardiotocography, fetal biophysical profile, amniotic fluid index and umbilical artery Doppler velocimetry. RESULTS: A total of 96 pregnancies with the following diagnoses were analyzed: gestational thrombocytopenia (n=37, 38.5%) hypersplenism (n=32, 33.3%), immune thrombocytopenic purpura (ITP, n=14, 14.6%), secondary immune thrombocytopenia (n=6, 6.3%), bone marrow aplasia (n=3, 3.1%), and others (n=4, 4.1%). Cardiotocography showed normal results in 94% of cases, a fetal biophysical profile with an index of 8 or 10 in 96.9% and an amniotic fluid index >5.0 cm in 89.6%. Doppler umbilical artery velocimetry showed normal results in 96.9% of cases. In the analysis of the major groups of thrombocytopenia, the diagnosis of oligohydramnios was found to be significantly more frequent in the group with ITP (28.6%) compared to the other groups (gestational thrombocytopenia: 5.4% and hypersplenism: 9.4%, p=0.04). CONCLUSIONS: This study indicates that in pregnancies complicated by moderate or severe maternal thrombocytopenia, even though the fetal well-being remains preserved in most cases, fetal surveillance is important in pregnant women with ITP, with emphasis on amniotic fluid volume evaluation due to its association with oligohydramnios
Resultados maternos e perinatais em gestantes portadoras de leucemia Maternal and perinatal outcomes in pregnant women with leukemia
RESUMO OBJETIVO: Descrever as complicações maternas e os resultados perinatais entre as gestantes com diagnóstico de leucemia que foram acompanhadas no pré-natal e no parto em hospital universitário. MÉTODOS: Estudo retrospectivo do perÃodo de 2001 a 2011, que incluiu 16 gestantes portadoras de leucemia acompanhadas pela equipe de pré-natal especializado em hemopatias e gestação. Nas leucoses agudas, diagnosticadas após o primeiro trimestre, a recomendação foi realizar a quimioterapia apesar da gestação em curso. Nas gestantes com leucoses crônicas, quando controladas do ponto de vista hematológico, foram mantidas sem medicação durante a gravidez, ou, foi introduzida terapêutica antineoplásica após o primeiro trimestre. Foram analisadas as complicações maternas e os resultados perinatais. RESULTADOS: A leucemia linfoide aguda (LLA) foi diagnosticada em cinco casos (31,3%), a leucemia mieloide aguda (LMA) em dois casos (12,5%) e a leucemia mieloide crônica (LMC) em nove casos (56,3%). Nos casos de leucemias agudas, dois (28,6%) casos foram diagnosticados no primeiro trimestre, dois (28,6%) no segundo e três (42,9%) no terceiro. Duas gestantes com LLA diagnosticada no primeiro trimestre optaram pelo aborto terapêutico. Quatro casos de leucemia aguda receberam tratamento quimioterápico na gestação, com diagnóstico estabelecido após a 20ª semana. Em um caso de LLA com diagnóstico tardio (30ª semana) a quimioterapia foi iniciada após o parto. Todas as gestantes com leucemia aguda evoluÃram com anemia e plaquetopenia, quatro casos (57,1%) evoluÃram com neutropenia febril. Das gestantes com LMC, quatro utilizavam mesilato de imatinibe quando engravidaram, três delas suspenderam no primeiro trimestre e uma no segundo. Durante a gravidez, três (33,3%) não necessitaram de terapêutica antineoplásica após suspensão do imatinibe; e em seis (66,7%) foram utilizadas as seguintes drogas: interferon (n=5) e/ou hidroxiureia (n=3). No grupo de gestantes com LMC, verificou-se a ocorrência de anemia em quatro casos (44,4%) e plaquetopenia em um (11,1%). Quanto aos resultados perinatais, nas gestações complicadas pela leucemia aguda, a média da idade gestacional no parto foi de 32 semanas (desvio padrão - DP=4,4) e a média do peso do recém-nascido foi 1476 g (DP=657 g). Houve 2 (40,0%) óbitos perinatais (um fetal e um neonatal). Nas gestações complicadas pela LMC, a média da idade gestacional no parto foi de 37,6 semanas (DP=1,1) e a média do peso do recém-nascido foi 2870 g (DP=516 g); não houve morte perinatal e nenhuma anomalia fetal foi detectada. CONCLUSÕES: É elevada a morbidade materna e fetal nas gestações complicadas pela leucemia aguda; enquanto que, nas complicadas pela LMC, o prognóstico materno e fetal parece ser mais favorável, com maior facilidade no manejo das complicações.PURPOSE: To describe the maternal and perinatal outcomes of pregnant women diagnosed with leukemia who were followed up for prenatal care and delivery at a university hospital. METHODS: A retrospective study of the period from 2001 to 2011, which included 16 pregnant women with a diagnosis of leukemia followed by antenatal care specialists in hematological diseases and pregnancy. For acute leukemia diagnosed after the first trimester, the recommendation was to perform chemotherapy despite the current pregnancy. For chronic leukemia, patients who were controlled in hematological terms were maintained without medication during pregnancy, or chemotherapy was introduced after the first trimester. We analyzed the maternal and perinatal outcome. RESULTS: Acute lymphoblastic leukemia (ALL) was diagnosed in five cases (31.3%), acute myeloid leukemia (AML) in two cases (12.5%) and chronic myeloid leukemia (CML) in nine cases (56.3%). Of the cases of acute leukemia, two (28.6%) were diagnosed in the first trimester, two (28.6%) in the second and three (42.9%) in the third. Two patients with ALL diagnosed in the first trimester opted for therapeutic abortion. Four patients with acute leukemia received chemotherapy during pregnancy, with a diagnosis established after the 20th week. In one case of ALL with a late diagnosis (30 weeks), chemotherapy was started after delivery. All pregnant women with acute leukemia developed anemia and thrombocytopenia, and four (57.1%) developed febrile neutropenia. Of nine pregnant women with CML, four were treated with imatinib mesylate when they became pregnant, with treatment being interrupted in the first trimester in three of them and in the second trimester in one. During pregnancy, three patients (33.3%) required no chemotherapy after discontinuation of imatinib, and six (66.7%) were treated with the following drugs: interferon (n=5) and/or hydroxyurea (n=3 ). In the group of pregnant women with CML, anemia occurred in four (44.4%) cases and thrombocytopenia in one (11.1%). The perinatal outcomes of pregnancies complicated by acute leukemia were as follows: mean gestational age at delivery was 32 weeks (standard deviation - SD=4.4) and the mean birth weight was 1476 g (SD=657 g), there were 2 (40.0%) perinatal deaths (a fetal one and a neonatal one). In pregnancies complicated by CML, the mean gestational age at delivery was 37.6 weeks (SD=1.1) and the mean birth weight was 2870 g (SD=516 g). There was no perinatal death and no fetal abnormality was detected. CONCLUSIONS: Maternal and fetal morbidity is high in pregnancies complicated by acute leukemia. Whereas, in pregnancies complicated by CML, the maternal and fetal prognosis appears to be more favorable, with greater ease in management of complications